| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-11-11 |
复牌提示：
2020-11-10 19:55:05 停牌，复牌日期 2020-11-12 00:00:01
|
| 2020-11-11 |
详情>>
内部人交易：
Porter Jonathan Wesley等共交易93笔
|
| 2020-11-02 |
详情>>
股本变动：
变动后总股本12993.48万股
|
| 2020-11-02 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.73美元,归母净利润-9402.1万美元,同比去年增长4.26%
|
| 2020-09-18 |
股东大会：
将于2020-10-28召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Report of our board of directors on the fiscal year ended December 29, 2019 (for discussion only).
3.Appointment of one executive director and eight non-executive directors and notification to the shareholders of the contemplated appointment of Robert J. Palmisano as executive director and David D. Stevens, Gary D. Blackford, J. Patrick Mackin, John L. Miclot, Kevin C. O’Boyle, Amy S. Paul, Richard F. Wallman and Elizabeth H. Weatherman as non-executive directors to serve until the 2021 Annual General Meeting or until his or her earlier death, resignation or removal (Voting Proposal No. 1).
4.Directors’ remuneration for the fiscal year ended December 29, 2019 (for discussion only).
5.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 27, 2020 (Voting Proposal No. 2).
6.Appointment of KPMG N.V. as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 27, 2020 (Voting Proposal No. 3).
7.Adoption of our Dutch statutory annual accounts for the fiscal year ended December 29, 2019 (Voting Proposal No. 4).
8.Release of each member of our board of directors from liability with respect to the exercise of his or her duties during the fiscal year ended December 29, 2019 (Voting Proposal No. 5).
9.Renewal of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until April 28, 2022 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction (Voting Proposal No. 6).
10.Renewal of the authority of our board of directors to issue ordinary shares or grant rights to subscribe for ordinary shares up to 20% of our issued and outstanding shares at the time of the issue until October 28, 2022 (Voting Proposal No. 7).
11.Renewal of the authority of our board of directors to resolve to exclude or restrict our shareholders’ pre-emptive rights under Dutch law with respect to the ordinary shares and rights to subscribe therefor that the board of directors may issue or grant pursuant to the authority in agenda item 10 above until October 28, 2022 (Voting Proposal No. 8).
12.Approval, on an advisory basis, of our executive compensation (Voting Proposal No. 9).
13.Closing.
|
| 2020-07-29 |
详情>>
业绩披露：
2020年中报每股收益-0.58美元,归母净利润-7429.9万美元,同比去年增长-36.55%
|
| 2020-05-08 |
详情>>
业绩披露：
2020年一季报每股收益-0.12美元,归母净利润-1490.6万美元,同比去年增长59.27%
|
| 2020-02-24 |
详情>>
业绩披露：
2019年年报每股收益-0.9美元,归母净利润-1.14亿美元,同比去年增长32.61%
|
| 2020-02-24 |
详情>>
业绩披露：
2017年年报每股收益-1.94美元,归母净利润-2.03亿美元,同比去年增长53.14%
|
| 2019-11-08 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-0.78美元,归母净利润-9820.2万美元,同比去年增长27.65%
|
| 2019-11-06 |
财报披露：
美东时间 2019-11-06 盘后发布财报
|
| 2019-08-08 |
详情>>
业绩披露：
2019年中报每股收益-0.43美元,归母净利润-5441.3万美元,同比去年增长41.62%
|
| 2019-08-08 |
详情>>
业绩披露：
2018年中报每股收益-0.88美元,归母净利润-9321.2万美元,同比去年增长6.66%
|
| 2019-05-17 |
股东大会：
将于2019-06-28召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Report of our board of directors on the fiscal year ended December 30, 2018 (for discussion only).
3.Appointment of one executive director and eight non-executive directors and notification to the shareholders of the contemplated appointment of Robert J. Palmisano as executive director and David D. Stevens, Gary D. Blackford, J. Patrick Mackin, John L. Miclot, Kevin C. O’Boyle, Amy S. Paul, Richard F. Wallman and Elizabeth H. Weatherman as non-executive directors to serve until the 2020 Annual General Meeting or until his or her earlier death, resignation or removal (Voting Proposal No. 1).
4.Directors’ remuneration for the fiscal year ended December 30, 2018 (for discussion only).
5.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 29, 2019 (Voting Proposal No. 2).
6.Appointment of KPMG N.V. as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 29, 2019 (Voting Proposal No. 3).
7.Adoption of our Dutch statutory annual accounts for the fiscal year ended December 30, 2018 (Voting Proposal No. 4).
8.Release of each member of our board of directors from liability with respect to the exercise of his or her duties during the fiscal year ended December 30, 2018 (Voting Proposal No. 5).
9.Extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 28, 2020 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction (Voting Proposal No. 6).
10.Limited authorization of our board of directors to issue ordinary shares or grant rights to subscribe for ordinary shares up to 20% of our issued and outstanding shares at the time of the issue until June 28, 2021 (Voting Proposal No. 7).
11.Limited authorization of our board of directors to resolve to exclude or restrict our shareholders’ pre-emptive rights under Dutch law with respect to the ordinary shares and rights to subscribe therefor that the board of directors may issue or grant pursuant to the authority in agenda item 10 above until June 28, 2021 (Voting Proposal No. 8).
12.Approval of the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan (Voting Proposal No. 9).
13.Approval, on an advisory basis, of our executive compensation (Voting Proposal No. 10).
14.Closing.
|
| 2019-05-08 |
详情>>
业绩披露：
2019年一季报每股收益-0.29美元,归母净利润-3660.1万美元,同比去年增长-43.45%
|
| 2019-02-27 |
详情>>
业绩披露：
2018年年报每股收益-1.51美元,归母净利润-1.7亿美元,同比去年增长16.33%
|
| 2018-11-08 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-1.25美元,归母净利润-1.36亿美元,同比去年增长41.42%
|
| 2018-05-15 |
股东大会：
将于2018-06-29召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Report of our board of directors on the fiscal year ended December 31, 2017 (for discussion only).
3.Appointment of one executive director and eight non-executive directors and notification to the shareholders of the contemplated appointment of Robert J. Palmisano as an executive director and David D. Stevens, Gary D. Blackford, J. Patrick Mackin, John L. Miclot, Kevin C. O’Boyle, Amy S. Paul, Richard F. Wallman and Elizabeth H. Weatherman as non-executive directors to serve until the 2019 annual general meeting of shareholders or until his or her earlier death, resignation or removal (voting proposal no. 1).
4.Directors’ remuneration for the fiscal year ended December 31, 2017 (for discussion only).
5.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 30, 2018 (voting proposal no. 2).
6.Appointment of KPMG N.V. as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 30, 2018 (voting proposal no. 3).
7.Adoption of our Dutch statutory annual accounts for the fiscal year ended December 31, 2017 (voting proposal no. 4).
8.Release of each member of our board of directors from liability with respect to the exercise of his or her duties during the fiscal year ended December 31, 2017 (voting proposal no. 5).
9.Extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 29, 2019 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction (voting proposal no. 6).
10.Approval, on an advisory basis, of our executive compensation (voting proposal no. 7).
11.Closing.
|
| 2017-05-10 |
股东大会：
将于2017-06-23召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Report of our board of directors on the fiscal year ended December 25, 2016 (for discussion only).
3.Appointment of one executive director and seven non-executive directors and notification to the shareholders of the contemplated appointment of Robert J. Palmisano as an executive director and David D. Stevens, Gary D. Blackford, John L. Miclot, Kevin C. O’Boyle, Amy S. Paul, Richard F. Wallman and Elizabeth H. Weatherman as non-executive directors to serve until the 2018 annual general meeting of shareholders or until his or her earlier death, resignation or removal (voting proposal no. 1).
4.Directors’ remuneration for the fiscal year ended December 25, 2016 (for discussion only).
5.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017 (voting proposal no. 2).
6.Appointment of KPMG N.V. as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 31, 2017 (voting proposal no. 3).
7.Adoption of our Dutch statutory annual accounts for the fiscal year ended December 25, 2016 (voting proposal no. 4).
8.Release of each member of our board of directors from liability with respect to the exercise of his or her duties during the fiscal year ended December 25, 2016 (voting proposal no. 5).
9.Extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 23, 2018 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction (voting proposal no. 6).
10.Approval of the Wright Medical Group N.V. 2017 Equity and Incentive Plan (voting proposal no. 7).
11.Approval, on an advisory basis, of our executive compensation (voting proposal no. 8).
12.Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation (voting proposal no. 9).
13.Closing.
|
| 2016-05-16 |
股东大会：
将于2016-06-28召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Report of our board of directors on the fiscal year ended December 27, 2015 (for discussion only).
3.Appointment of one executive director and eight non-executive directors and notification to the shareholders of the contemplated appointment of Robert J. Palmisano as an executive director and David D. Stevens, Gary D. Blackford, Sean D. Carney, John L. Miclot, Kevin C. O’Boyle, Amy S. Paul, Richard F. Wallman and Elizabeth H. Weatherman as non-executive directors to serve until the 2017 annual general meeting of shareholders or until his or her earlier death, resignation or removal (voting proposal no. 1).
4.Directors’ remuneration for the fiscal year ended December 27, 2015 (for discussion only).
5.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 25, 2016 (voting proposal no. 2).
6.Appointment of KPMG N.V. as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 25, 2016 (voting proposal no. 3).
7.Adoption of our Dutch statutory annual accounts for the fiscal year ended December 27, 2015 (voting proposal no. 4).
8.Release of the members of our board of directors from liability with respect to the exercise of their duties during the fiscal year ended December 27, 2015 (voting proposal no. 5).
9.Extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 28, 2017 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction (voting proposal no. 6).
10.Renewal of the authorization of our board of directors to issue ordinary shares or grant rights to subscribe for ordinary shares up to our maximum authorized share capital at the time of the issue until June 28, 2021 (voting proposal no. 7).
11.Renewal of the authorization of our board of directors to resolve to exclude or restrict our shareholders’ pre-emptive rights under Dutch law with respect to the ordinary shares and rights to subscribe therefor that the board of directors may issue or grant pursuant to the authority in agenda item 10 above until June 28, 2021 (voting proposal no. 8).
12.Approval of the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan (voting proposal no. 9).
13.Amendment of our articles of association to provide that our fiscal year runs from the first Monday after the last Sunday of December of a year and ends on the last Sunday of December of the following year (voting proposal no. 10).
14.Closing.
|
| 2015-05-14 |
股东大会：
将于2015-06-18召开股东大会
会议内容 ▼▲
- 1.Opening.
2.Report of our board of directors on the fiscal year ended December 28, 2014 (for discussion only).
3.Appointment of two non-executive directors and notification to the shareholders of the contemplated appointment of Sean D. Carney and Richard B. Emmitt as non-executive directors to serve until the earlier of: (a) the 2018 annual general meeting of shareholders; (b) the completion of our proposed merger with Wright Medical Group, Inc. and the appointment of directors in connection therewith; or (c) until their earlier death, resignation or removal.
4.Directors’ remuneration for the fiscal year ended December 28, 2014 (for discussion only).
5.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 27, 2015, assuming the proposed merger with Wright is not completed during the fiscal year 2015, and therefore, subject to a condition subsequent if the proposed merger with Wright is completed during the fiscal year 2015.
6.Appointment of E&Y Accountants LLP as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 27, 2015, assuming the proposed merger with Wright is not completed during the fiscal year 2015, and therefore, subject to a condition subsequent if the proposed merger with Wright is completed during the fiscal year 2015.
7.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 27, 2015, assuming the proposed merger with Wright is completed during the fiscal year 2015, and therefore, subject to a condition precedent that the proposed merger with Wright is completed during the fiscal year 2015.
8.Appointment of KPMG N.V. as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 27, 2015, assuming the proposed merger with Wright is completed during the fiscal year 2015, and therefore, subject to a condition precedent that the proposed merger with Wright is completed during the fiscal year 2015.
9.Adoption of our Dutch statutory annual accounts for the fiscal year ended December 28, 2014.
10.Release of the members of our board of directors from liability with respect to the exercise of their duties during the fiscal year ended December 28, 2014.
11.Extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 18, 2016 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction.
12.Renewal of the authorization of our board of directors to issue ordinary shares or grant rights to subscribe for ordinary shares up to our maximum authorized share capital at the time of the issue until June 18, 2020.
13.Renewal of the authorization of our board of directors to resolve to exclude or restrict our shareholders’ pre-emptive rights under Dutch law with respect to the ordinary shares and rights to subscribe therefor that the board of directors may issue or grant pursuant to the authority in agenda item 12 above until June 18, 2020.
14.Approval of the Tornier N.V. Amended and Restated 2010 Incentive Plan.
15.Closing.
|
| 2014-05-16 |
股东大会：
将于2014-06-26召开股东大会
会议内容 ▼▲
- 1. Opening;
2. Report of the Board of Directors on the fiscal year ended December 29, 2013 (for discussion only);
3. Election of two non-executive directors and notification to the shareholders of the contemplated appointment of Alain Tornier and Elizabeth H. Weatherman as non-executive directors to serve until the 2017 annual general meeting of shareholders or until their earlier death, resignation or removal (voting proposal no. 1);
4. Directors’ remuneration for the fiscal year ended December 29, 2013 (for discussion only);
5. Advisory vote on the compensation of our named executive officers as disclosed in the accompanying proxy statement pursuant to the rules of the U.S. Securities and Exchange Commission (voting proposal no. 2);
6. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 28, 2014 (voting proposal no. 3);
7. Appointment of E&Y Accountants LLP as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 28, 2014 (voting proposal no. 4);
8. Adoption of our Dutch statutory annual accounts for the fiscal year ended December 29, 2013 (voting proposal no. 5);
9. Authorization of the preparation of our Dutch statutory annual accounts and annual report of the Board of Directors required by Dutch law in the English language (voting proposal no. 6);
10. Release of the members of our board of directors from liability with respect to the exercise of their duties during the fiscal year ended December 29, 2013 (voting proposal no. 7);
11. Extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 26, 2015 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction (voting proposal no. 8);
12. Renewal of the authorization of our board of directors to issue ordinary shares or grant rights to subscribe for ordinary shares up to our maximum authorized share capital at the time of the issue until June 26, 2019 (voting proposal no. 9);
13. Renewal of the authorization of our board of directors to resolve to exclude or restrict our shareholders’ pre-emptive rights under Dutch law with respect to the ordinary shares and rights to subscribe therefor that the board of directors may issue or grant pursuant to the authority in agenda item 12 above until June 26, 2019 (voting proposal no. 10);
14. To consider such other business as may properly come before the meeting;
15. Closing.
|
| 2013-05-17 |
股东大会：
将于2013-06-27召开股东大会
会议内容 ▼▲
- 1. To elect three directors as named herein, consisting of one executive director and two non-executive directors, to serve until the 2016 annual general meeting of shareholders or until their earlier death, resignation or removal;
2. To amend our articles of association regarding conflicts of interest of directors to conform to recent changes in the Dutch Civil Code and to authorize the chairman of our board of directors and each employee of our outside Dutch counsel, Stibbe N.V., to sign the notarial deed of amendment to our articles of association in front of a civil-law notary in officiating in Amsterdam, the Netherlands and to undertake all other activities the holder of this power of attorney deems necessary or useful with respect to the proposed amendment to our articles of association;
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 29, 2013;
4. To appoint E&Y Accountants LLP as the auditor for our Dutch statutory annual accounts for the fiscal year ending December 29, 2013;
5. To adopt our Dutch statutory annual accounts for the fiscal year ended December 30, 2012;
6. To release the members of our board of directors from liability with respect to the exercise of their duties during the fiscal year ended December 30, 2012;
7. To approve the extension of the authority of our board of directors to repurchase up to 10% of our issued share capital (including depositary receipts issued for our shares) until December 27, 2014 on the open market, through privately negotiated transactions or in one or more self-tender offers for a price per share (or depositary receipt) not less than the nominal value of a share and not higher than 110% of the market price of a share (or depositary receipt) at the time of the transaction;
8. To transact such other business as may properly come before the meeting.
|